跳至主要内容
临床试验/EUCTR2019-003821-70-PL
EUCTR2019-003821-70-PL进行中(未招募)1 期

Evaluating the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients with Iron Deficiency Anemia and an Unsatisfactory Response to Oral Iron under Study Protocol 1VIT17044

American Regent, Inc.0 个研究点目标入组 10 人开始时间: 2019年11月28日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • 1. Unsatisfactory response to oral iron or those that required a concomitant intervention, (defined as, blood transfusion, use of IV or oral iron outside of protocol,
  • increase in erythropoietin for any reason [Day 0 thru Day 35 of study protocol 1VIT17044], change in Inflammatory Bowel Disease [IBD] treatment).
  • 2. Hgb <11 g/dL
  • 3. Ferritin =300 ng/dL and Transferrin Saturation (TSAT) <30%
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 36
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Known history of hypersensitivity reaction to any component of FCM.
  • 2. History of acquired iron overload, hemochromatosis, or other iron accumulation disorders.
  • 3. History of significant diseases of the liver, hematopoietic system, cardiovascular system, psychiatric disorder, or other conditions which, in the opinion of the investigator, may place a subject at added risk for participation in the study.
  • 4. Any existing non-viral infection.
  • 5. Known history of positive hepatitis B surface antigen (HBsAg) or hepatitis C viral antibody (HCV) with evidence of active hepatitis.
  • 6. Known history of positive human immunodeficiency virus (HIV-1/HIV-2) antibodies (anti-HIV).
  • 7. Anemia due to reasons other than iron deficiency (e.g., hemoglobinopathy and vitamin B12 or folic acid deficiency) that has not been corrected.
  • 8. Administration and / or use of an investigational product (drug or device) within 30 days of screening.
  • 9. Alcohol or drug abuse within the past six months.
  • 10. Female participant who is pregnant or lactating, or sexually active females who are of childbearing potential not willing to use an acceptable form of contraceptive
  • precautions during the study.
  • 11. Unable to comply with study procedures and assessments.

研究者

相似试验